We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Peakadilly Awarded €1.7 Million Grant by Flanders Government

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peakadilly Awarded €1.7 Million Grant by Flanders Government "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Peakadilly NV has announced that it has been awarded a grant extension from the Flanders Government to accelerate the development of its protein biomarker discovery platform. This brings the total value of the grant to €1.7 million.

This grant will support Peakadilly in expanding its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products.

The Company has already secured a series of granted patents and revenue-generating projects with pharma.

The grant was awarded by the Flanders Government through IWT-Flanders, the Institute for the Promotion of Innovation by Science and Technology in Flanders.

Commenting on the grant, Dr Koen Kas, Founder and CSO said, "Together with our income from R&D partnerships this grant has helped us to build Peakadilly and to attract one of the biggest rounds of European series A VC financing, which we closed last month."

"Moving forward, our goal is to deliver proof of concept for the development of the first high throughput mass spectrometry based serum protein profiling assay as we progress in the development of next generation molecular diagnostics."

Peakadilly has implemented a protein biomarker discovery technology that will transform the potential of protein biomarkers in molecular diagnostics and drug discovery and development.

The Company’s protein biomarker discovery operation is based on its proprietary MASStermind™ technology and includes the development of blood sample depletion technologies and chromatographic approaches, as well as mass spectrometry techniques and data interpretation methods.